Open Orphan to begin first-ever COVID-19 challenge trial

pharmafile | May 6, 2022 | News story | Medical Communications  

Open Orphan has been appointed by an unnamed existing “big pharma” client to host a Phase II field study of a potential vaccine for respiratory syncytial virus (RSV).

CEO Yamin ‘Mo’ Khan said that the deal was important as it represented the first time the company has been charged with carrying out a full-scale evaluation of this kind.

“To date, we have mainly acted as a contract research organisation to provide either challenge studies, laboratory or consulting services,” he explained.

“Although we have acted as a site as part of the challenge studies, we have not provided stand-alone site services.”

The company’s executive chairman expects to attract more high quality long-term investors, following the end of the lock-up arrangement with Poolbeg Pharma over legacy in specie shares.

Cathal Frie said: “Due to the nature of the lock-up period, which was designed to allow for an orderly market following Poolbeg’s admission to AIM, prospective investors looking to build more substantial stakes were unable to do so.”

Building on Open Orphan’s many years of challenge studies and virology research, the company is now developing an in-depth database of infectious disease progression data. The company’s Paris office has been providing biometry, data management, and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a diverse range of European clients.

Lina Adams


Related Content

No items found

Latest content